Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

50

Expected Date of Accrual

31 December 2026

Trial Chairperson

Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia

Trial Contact

qa@trog.com.au

Related Post

28 March, 2025

TROG Awards Recognise Research Excellence

Latest news: 28 March 2025. TROG Members who have

27 March, 2025

TROG 2025 ASM advances inclusivity and innovation

Latest news: 27 March 2025 With a theme of